Eli Lilly and Company Acquires Point and Signs Supply Agreement
1 report, 1 independent
Updated 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company acquired Point and signed a supply agreement with EUZ on October 19, 2026. The reports note that EUZ is positioned as an independent supplier in the expanding radiopharma market.
From finanznachrichten.de
Why it matters
The radiopharma market is expected to see significant growth, with market forecasts implying a 23% compound annual growth rate for Lu-177 and 45% for Ac-225 through 2035. Consistent purity and reliable output at scale create high barriers to entry for isotope production.
From finanznachrichten.de
Who's involved
- Eli Lilly and CompanyAcquired Point and established a supply agreement with EUZ.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Might secure long-term Lu-177 supply via the supply chain.
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company